Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.33 USD | +1.38% | -0.44% | -9.38% |
Apr. 11 | Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy | MT |
Apr. 03 | Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.38% | 1.64B | |
+26.08% | 653B | |
+27.00% | 556B | |
-6.64% | 354B | |
+20.90% | 331B | |
+2.27% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.07% | 144B |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Goldman Sachs Raises Price Target on Harmony Biosciences to $58 From $56, Maintains Neutral Rating